MTOR and cancer: It was recently reported that the mTOR pathway mediated the non-canonical Hh signaling cascade to induce PD-L1 expression [54], and that increased HH activity was a predictive biomarker for resistance to immune checkpoint inhibitors in diverse cancers [51].